Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

The glutamine story: where are we now?

Publication ,  Journal Article
Wischmeyer, PE
Published in: Curr Opin Crit Care
April 2006

PURPOSE OF REVIEW: A recent editorial proclaimed, 'Glutamine, a life saving nutrient, but why?' This review will assess if recent data support glutamine as a life-saving nutrient in critical illness, and, if so, utilize new understanding of gene-nutrient interactions to address potential mechanisms by which glutamine may be 'life-saving'. RECENT FINDINGS: Updated meta-analysis data reveal that glutamine appears to exert a beneficial effect on mortality in critical illness. The questions remaining to be answered regard in what settings and via what method of administration does this phamaconutrient show optimal benefit? It is likely that examination of molecular mechanisms by which glutamine functions will lead to an understanding of how best to utilize glutamine as a pharmacologic agent. Recent laboratory data reveal that these mechanisms include tissue protection, attenuation of inflammation, improved tissue metabolic function, and attenuation of oxidant stress. SUMMARY: Glutamine may be potentially 'life-saving' in critical illness, particularly when administered in doses greater then 0.3 g/kg/day. Present data indicate that glutamine functions as a 'stress signaling molecule' following illness/injury and thus, needs to be given as a pharmacologic agent, rather then as nutritional replacement. Presently, multicenter clinical trials utilizing glutamine as a drug, independent of nutritional needs, are indicated.

Duke Scholars

Published In

Curr Opin Crit Care

DOI

ISSN

1070-5295

Publication Date

April 2006

Volume

12

Issue

2

Start / End Page

142 / 148

Location

United States

Related Subject Headings

  • Meta-Analysis as Topic
  • Humans
  • HSP70 Heat-Shock Proteins
  • Glutamine
  • Emergency & Critical Care Medicine
  • Critical Care
  • Clinical Trials as Topic
  • Burns
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wischmeyer, P. E. (2006). The glutamine story: where are we now? Curr Opin Crit Care, 12(2), 142–148. https://doi.org/10.1097/01.ccx.0000216582.87674.a4
Wischmeyer, Paul E. “The glutamine story: where are we now?Curr Opin Crit Care 12, no. 2 (April 2006): 142–48. https://doi.org/10.1097/01.ccx.0000216582.87674.a4.
Wischmeyer PE. The glutamine story: where are we now? Curr Opin Crit Care. 2006 Apr;12(2):142–8.
Wischmeyer, Paul E. “The glutamine story: where are we now?Curr Opin Crit Care, vol. 12, no. 2, Apr. 2006, pp. 142–48. Pubmed, doi:10.1097/01.ccx.0000216582.87674.a4.
Wischmeyer PE. The glutamine story: where are we now? Curr Opin Crit Care. 2006 Apr;12(2):142–148.

Published In

Curr Opin Crit Care

DOI

ISSN

1070-5295

Publication Date

April 2006

Volume

12

Issue

2

Start / End Page

142 / 148

Location

United States

Related Subject Headings

  • Meta-Analysis as Topic
  • Humans
  • HSP70 Heat-Shock Proteins
  • Glutamine
  • Emergency & Critical Care Medicine
  • Critical Care
  • Clinical Trials as Topic
  • Burns
  • 3202 Clinical sciences
  • 1103 Clinical Sciences